The Sharing Alliance™, a DBA of The PDMA Alliance Inc., is a not-for-profit organization dedicated to the ongoing education of its members on compliance best practices. The Alliance is well aware of the issues challenging pharmaceutical, medical device and biotech compliance professionals and we support our members with valuable, timely information on all the important legislative requirements of pharmaceutical compliance, both state and federal. We haven’t lost touch with our PDMA roots: instead, we’ve expanded to deliver even more to the compliance community.
The Alliance maintains good relationships with the U.S. Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS), the Office of Inspector General (OIG) and other agencies and organizations to continually understand and educate the industry on pharmaceutical compliance business and security best practices. The Alliance Board is committed to the ongoing expansion of the not-for-profit Alliance by supporting members through dynamic pharmaceutical industry changes and challenges.
Our mission: to improve the understanding of laws and regulations that most impact the compliance professionals that make up our membership; to help facilitate the communication and sharing of compliance best practices; to continue the legacy of excellence the Alliance has held for over the past 25 years.
Our founding: In 1990, a group of pharmaceutical executives responsible for compliance to the Prescription Drug Marketing Act of 1987 (PDMA), came together to discuss the relatively new PDMA and how it was impacting their work days. They shared ideas and networked on issues related to sample accountability. The group grew to become The Alliance, the industry voice of pharmaceutical compliance professionals.
-
Industry
-
Pharmaceutical Manufacturing
-
Company size
-
201-500 employees
-
Headquarters
-
Valhalla, NY
-
Type
-
Nonprofit
-
Founded
-
1990
-
Specialties
-
Regulatory Compliance, Prescription Drug Marketing Act, OIG Guidelines, Open Payments, Investigations, Drug Supply Chain Security Act, Corporate Integrity Agreements, and Aggregate Spend
